Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

4 Issues per year


CiteScore 2017: 2.48

SCImago Journal Rank (SJR) 2017: 1.021
Source Normalized Impact per Paper (SNIP) 2017: 0.830

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 29, Issue 3

Issues

Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index

Eleni Alexiou
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Erifili Hatziagelaki
  • Second Department of Internal Medicine, Research Institute and Diabetes Center, “Attikon” Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Vasilios Pergialiotis
  • Corresponding author
  • Third Department of Obstetrics and Gynecology, University of Athens, Attikon University Hospital Athens Greece, Rimini 1 Chaidari, Athens, PC 12461, Greece, Phone: 2105832244, Fax: 2105326447
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Charalampos Chrelias
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Dimitrios Kassanos
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Charalampos Siristatidis
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Giannoula Kyrkou
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria Kreatsa
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eftihios Trakakis
  • Third Department of Obstetrics and Gynecology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-01-18 | DOI: https://doi.org/10.1515/hmbci-2016-0047

Abstract

Background:

Hyperandrogenemia is one of the major diagnostic features for the diagnosis of polycystic ovary syndrome (PCOS). The aim of this study was to estimate the prevalence and the characteristics of hyperandrogenemia in women with PCOS and to investigate the association of clinical and biochemical characteristics with body mass index (BMI) according to the presence of hyperandrogenemia.

Materials and methods:

We studied 266 women diagnosed with PCOS. Hyperandrogenemia was defined by testosterone (T) and/or free testosterone (FT) and/or ∆4 androstenedione (Δ4-A) higher than 75% of the upper limits of each hormone. Patients were stratified in two groups according to a BMI threshold of 25 kg/m2.

Results:

Hyperandrogenemia was present in 78.2% of the patients. Elevated levels of T were found in 58.4%, while elevated levels of FT and Δ4-A were found in 42.5% and 34.1% of patients. In normal weight women (BMI≤25 kg/m2) with hyperandrogenemia lower values of hip circumference and HOMA-IR and increased levels of T, FT, Δ4-A, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEAS), white blood cells (WBC) and neutrophils were observed compared to women without hyperandrogenemia. Also, in overweight women higher levels of T, FT, Δ4-A, 17-OHP, DHEAS and cortisol were measured, while lower thyroid-stimulating hormone (TSH) levels were comparable to women without hyperandrogenemia.

Conclusion:

This study showed high prevalence of hyperandrogenemia in PCOS women. Women with BMI≤25 kg/m2 have significant differences in androgens, WBC, neutrophils and HOMA-IR and women with BMI≥25 kg/m2 in androgens, TSH and cortisol according to the presence or not of hyperandrogenemia.

Keywords: androstendione; DHEAS; hyperandrogenemia; PCOS; testosterone

References

  • 1.

    Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841–55.Google Scholar

  • 2.

    Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014;29:791–801.Google Scholar

  • 3.

    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.Google Scholar

  • 4.

    Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011;26:3138–46.Google Scholar

  • 5.

    Powell BL, Haddad L, Bennett A, Gharani N, Sovio U, Groves CJ, Rush K, Goh MJ, Conway GS, Ruokonen A, Martikainen H, Pouta A, Taponen S, Hartikainen AL, Halford S, Zeggini E, Jarvelin MR, Franks S, McCarthy MI. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab 2005;90:2988–93.Google Scholar

  • 6.

    Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: investigations and management. Best Pract Res Clin Obstet Gynaecol 2016;37:98–118.Google Scholar

  • 7.

    Livadas S, Diamanti-Kandarakis E. Polycystic ovary syndrome: definitions, phenotypes and diagnostic approach. Front Horm Res 2013;40:1–21.Google Scholar

  • 8.

    Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010;93:1938–41.Google Scholar

  • 9.

    Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, Kaldrymides P, Panidis D, Diamanti-Kandarakis E. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014;47:631–8.Google Scholar

  • 10.

    Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol 2010;162:611–5.Google Scholar

  • 11.

    Cho LW, Kilpatrick ES, Jayagopal V, Diver MJ, Atkin SL. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf) 2008;68:390–4.Google Scholar

  • 12.

    Golbahar J, Al-Ayadhi M, Das NM, Gumaa K. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain. Int J Womens Health 2012;4:201-206.Google Scholar

  • 13.

    Pinola P, Piltonen TT, Puurunen J, Vanky E, Sundstrom-Poromaa I, Stener-Victorin E, Ruokonen A, Puukka K, Tapanainen JS, Morin-Papunen LC. Androgen profile through life in women with polycystic ovary syndrome: a nordic multicenter collaboration study. J Clin Endocrinol Metab 2015;100:3400–7.Google Scholar

  • 14.

    Olszanecka A, Kawecka-Jaszcz K, Czarnecka D. Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal women. Arch Med Sci 2016;12:521–8.Google Scholar

  • 15.

    Guducu N, Kutay SS, Gormus U, Kavak ZN, Dunder I. High DHEAS/free testosterone ratio is related to better metabolic parameters in women with PCOS. Gynecol Endocrinol 2015;31:495–500.Google Scholar

  • 16.

    Georgopoulos NA, Papadakis E, Armeni AK, Katsikis I, Roupas ND, Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014;13:213–21.Google Scholar

  • 17.

    Papalou O, Livadas S, Karachalios A, Tolia N, Kokkoris P, Tripolitakis K, Diamanti-Kandarakis E. White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones (Athens) 2015;14:91–100.Google Scholar

  • 18.

    Clark CM, Rudolph J, Gerber DA, Glick S, Shalita AR, Lowenstein EJ. Dermatologic manifestation of hyperandrogenism: a retrospective chart review. Skinmed 2014;12:84–8.Google Scholar

  • 19.

    Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, Lee J, Zane LT, Shinkai K. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol 2016;152:391–8.Google Scholar

  • 20.

    Hong JS, Kwon HH, Park SY, Jung JY, Yoon JY, Min S, Choi YM, Suh DH. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. J Eur Acad Dermatol Venereol 2015;29:42–7.Google Scholar

  • 21.

    Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril 2014;101:1129–34.Google Scholar

  • 22.

    Luque-Ramirez M, Escobar-Morreale HF. Adrenal hyperandrogenism and polycystic ovary syndrome. Curr Pharm Des 2016;22:5588–602.Google Scholar

About the article

Received: 2016-10-10

Accepted: 2016-11-29

Published Online: 2017-01-18

Published in Print: 2017-03-01


Author Statement

Funding: Authors state no funding involved.

Conflict of interest: Authors state no conflict of interest.

Informed consent: Informed consent has been obtained from all individuals included in this study.

Ethical approval: The research related to human use complied with all the relevant national regulations, institutional policies and was performed in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 29, Issue 3, Pages 105–111, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: https://doi.org/10.1515/hmbci-2016-0047.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
María V. Scalerandi, Nahuel Peinetti, Carolina Leimgruber, Mariana M. Cuello Rubio, Juan P. Nicola, Gustavo B. Menezes, Cristina A. Maldonado, and Amado A. Quintar
Frontiers in Immunology, 2018, Volume 9

Comments (0)

Please log in or register to comment.
Log in